Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Halbert

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Clinical Pathology|March 25, 2006
Immunohistochemical staining for adipophilin, perilipin and TIP47K Muthusamy, G Halbert, F Roberts
Journal of Immunoassay & Immunochemistry|July 7, 2007
Salmonella enterica Serotype Urbana Interference with Brucellosis SerologyK Nielsen, P Smith, W L Yu, et al.
International Journal of Pharmaceutics|February 10, 2023
Development and implementation of a pneumatic micro-feeder for poorly-flowing solid pharmaceutical materialsP Hou, M O Besenhard, G Halbert, et al.
International Journal of Pharmaceutics|July 28, 2024
A continuous micro-feeder for cohesive pharmaceutical materialsP Hou, M O Besenhard, G Halbert, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1984
The analysis and animal pharmacokinetics of 1,2,4, triglycidyl urazol using a high-pressure liquid chromatographic techniqueJ Welsh, J F Stuart, A Setanoians, et al.
British Journal of Cancer|May 20, 2004
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancerS Danson, D Ferry, V Alakhov, et al.
British Journal of Cancer|October 2, 2003
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinomaA R Clamp, F H Blackhall, P Vasey, et al.
British Journal of Cancer|May 20, 2004
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerA O'Donnell, I Judson, M Dowsett, et al.
British Journal of Cancer|April 17, 2003
5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic studyG J S Rustin, C Bradley, S Galbraith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2007
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I studyW P Steward, M Middleton, A Benghiat, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pathology|March 25, 2006
Immunohistochemical staining for adipophilin, perilipin and TIP47K Muthusamy, G Halbert, F Roberts
Journal of Immunoassay & Immunochemistry|July 7, 2007
Salmonella enterica Serotype Urbana Interference with Brucellosis SerologyK Nielsen, P Smith, W L Yu, et al.
International Journal of Pharmaceutics|February 10, 2023
Development and implementation of a pneumatic micro-feeder for poorly-flowing solid pharmaceutical materialsP Hou, M O Besenhard, G Halbert, et al.
International Journal of Pharmaceutics|July 28, 2024
A continuous micro-feeder for cohesive pharmaceutical materialsP Hou, M O Besenhard, G Halbert, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1984
The analysis and animal pharmacokinetics of 1,2,4, triglycidyl urazol using a high-pressure liquid chromatographic techniqueJ Welsh, J F Stuart, A Setanoians, et al.
British Journal of Cancer|May 20, 2004
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancerS Danson, D Ferry, V Alakhov, et al.
British Journal of Cancer|October 2, 2003
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinomaA R Clamp, F H Blackhall, P Vasey, et al.
British Journal of Cancer|May 20, 2004
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerA O'Donnell, I Judson, M Dowsett, et al.
British Journal of Cancer|April 17, 2003
5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic studyG J S Rustin, C Bradley, S Galbraith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2007
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I studyW P Steward, M Middleton, A Benghiat, et al.
Pageof 2